Serum thrombomodulin in sensitive and refractory GVHD patients. (A) Time course of individual sTM levels (pg/mL) in 22 patients with therapy-sensitive (left panel) and 25 patients with refractory GVHD (right panel). Shown are the individual data points and linear regression lines for each patient. (B) Absolute serum levels of sTM in individual sensitive (n = 23, left panel) and refractory (n = 25, right panel) GVHD patients at escalation of immunosuppression (“escalation”) and during the “follow-up” period (days 20-90 after escalating immunosuppression). Lines represent the medians. Wilcoxon signed-rank test was applied.